Treatment considerations in myasthenia gravis for the pregnant patient

References

• Gilhus NE, Gravis M. Myasthenia Gravis. N Engl J Med. 2016 Dec;375(26):2570–2581.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023–1036.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018 Jan;11:1–11.
   Web of Science ®Google Scholar
• Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes. 2015;13(1):1-15.
   PubMedGoogle Scholar
• Ohlraun S, Hoffmann S, Klehmet J, et al. Impact of myasthenia gravis on family planning: how do women with myasthenia gravis decide and why? Muscle Nerve. 2015 Sep;52(3):371–379.
   PubMed Web of Science ®Google Scholar
• Andersen JB, Heldal AT, Engeland A, et al. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand. 2014 Apr;129:26–31.
   Web of Science ®Google Scholar
• Gilhus NE. Myasthenia Gravis can have consequences for pregnancy and the developing child. Front Neurol. 2020 Jun;11:1-6.
   PubMed Web of Science ®Google Scholar
• Heldal AT, Owe JF, Gilhus NE, et al. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009 Jul 14;73(2):150–151.
   PubMed Web of Science ®Google Scholar
• Andersen JB, Engeland A, Owe JF, et al. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol. 2010 Dec;17(12):1445–1450.
   PubMed Web of Science ®Google Scholar
• Hong Y, Skeie GO, Zisimopoulou P, et al. Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms. J Neurol. 2017 May;264(5):955–962.
   PubMed Web of Science ®Google Scholar
• Chen JS, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Regional Health-Western Pacific. 2020 Dec;5:100063.
   PubMedGoogle Scholar
• Hong Y, Li HF, Romi F, et al. HLA and MuSK-positive myasthenia gravis: a systemic review and meta-analysis. Acta Neurol Scand. 2018 Sep;138(3):219–226.
   PubMed Web of Science ®Google Scholar
• Rodolico C, Bonanno C, Toscano A, et al. MuSK-associated myasthenia gravis: clinical features and management. Front Neurol. 2020; 11:1-5.
   Web of Science ®Google Scholar
• Evoli A, Alboini PE, Damato V, et al. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018 Jan;1412(1):82–89.
   PubMed Web of Science ®Google Scholar
• Hong Y, Zisimopoulou P, Trakas N, et al. Multiple antibody detection in ‘seronegative’ myasthenia gravis patients. Eur J Neurol. 2017 Jun;24(6):844–850.
   PubMed Web of Science ®Google Scholar
• Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014 May;21(5):687–693.
   PubMed Web of Science ®Google Scholar
• Marx A, Yamada Y, Simon-Keller K, et al. Thymus and autoimmunity. Semin Immunopathol. 2021 Feb;43(1):45–64.
   PubMed Web of Science ®Google Scholar
• Ramanujam R, Pirskanen R, Ramanujam S, et al. Utilizing twins concordance rates to infer the predisposition to myasthenia gravis. Twin Res Human Genet. 2011 Apr;14(2):129–136.
   PubMed Web of Science ®Google Scholar
• Pirskanen R. Genetic aspects in myasthenia gravis - family study of 264 Finnish patients. Acta Neurol Scand. 1977;56(5):365–388.
   PubMed Web of Science ®Google Scholar
• Salvado M, Canela M, Maria J, et al. Study of the prevalence of familial autoimmune myasthenia gravis in a Spanish cohort. J Neurol Sci. 2016 Jan;360:110–114.
   PubMed Web of Science ®Google Scholar
• Liu FC, Kuo CF, See LC, et al. Familial aggregation of myasthenia gravis in affected families: a population-based study. Clin Epidemiol. 2017;9:527–535.
   PubMed Web of Science ®Google Scholar
• Gilhus NEHY. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol. 2018;25:1–8.
   Web of Science ®Google Scholar
• Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell. 1996 May;85(3):311–318.
   PubMed Web of Science ®Google Scholar
• Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry. 2014 May;85(5):538–543.
   PubMed Web of Science ®Google Scholar
• Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis - Consequences for pregnancy, delivery, and the newborn. Neurology. 2003 Nov;61(10):1362–1366.
   PubMed Web of Science ®Google Scholar
• Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010 Jul;17(7):893–902.
   PubMed Web of Science ®Google Scholar
• Evoli A. Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol. 2017 Oct;30(5):464–470.
   PubMed Web of Science ®Google Scholar
• Levy RA, de Jesus GR, de Jesus NR, et al. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev. 2016 Oct;15(10):955–963.
   PubMed Web of Science ®Google Scholar
• Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–425.
   PubMed Web of Science ®Google Scholar
• Reynolds JA, Gayed M, Khamashta MA, et al. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology. 2022;00:1-12
   Web of Science ®Google Scholar
• Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf. 2021 Mar;20(3):275–291.
   PubMed Web of Science ®Google Scholar
• Sharma UR, Rathnakaran AN, Raj BPP, et al. The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy. Inflammopharmacology. 2021 Aug;29(4):987–1000.
   PubMed Web of Science ®Google Scholar
• Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Can Med Assoc J. 2011 Apr;183(7):796–804.
   PubMed Web of Science ®Google Scholar
• Thalluri V, Woodman RJ, Vollenhoven B, et al. Exposure to corticosteroids in the first trimester is associated with an increased risk of urogenital congenital anomalies. Hum Reprod. 2022 Aug;37(9):2167–2174.
   PubMed Web of Science ®Google Scholar
• Odufalu FD, Long ML, Lin K, et al. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut. 2022 Sep;71(9):1766–1772.
   PubMed Web of Science ®Google Scholar
• Dao KH, Bermas BL. Systemic Lupus erythematosus management in pregnancy. Int J Womens Health. 2022;14:199–211.
   PubMed Web of Science ®Google Scholar
• Talabi MB, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol. 2020 May;32(3):238–246.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li DD, Guo H, et al., Association between thiopurines use and pregnancy outcomes in female patients with inflammatory bowel disease: a meta-analysis. Curr Pharm Des. 2021;27(19): 2317–2324.
   PubMed Web of Science ®Google Scholar
• Flanagan E, Wright EK, Hardikar W, et al. Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Aliment Pharmacol Ther. 2021 Apr;53(7):810–820.
   PubMed Web of Science ®Google Scholar
• Sanders DB, Wolfe GI, Narayanaswami P, et al. Developing treatment guidelines for myasthenia gravis. Ann N Y Acad Sci. 2018 Jan;1412(1):95–101.
   PubMed Web of Science ®Google Scholar
• Meinderts JRR, Prins JRR, Berger SPP, et al. Follow-up of offspring born to parents with a solid organ transplantation: a systematic review. Transplant Int. 2022 Aug;35:1-12.
   PubMed Web of Science ®Google Scholar
• Akiyama S, Hamdeh S, Murakami N, et al. Pregnancy and neonatal outcomes in women receiving calcineurin inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022 Sep;88(9):3950–3961.
   PubMed Web of Science ®Google Scholar
• Zhao C, Pu M, Chen DW, et al. Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis. Front Neurol. 2021 Oct;12:1-10.
   Web of Science ®Google Scholar
• Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis The BeatMG Study. Neurology. 2022 Jan;98(4):E376–E389.
   Web of Science ®Google Scholar
• Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis The RINOMAX randomized clinical trial. JAMA Neurol. 2022;79:1105-1112.
   Web of Science ®Google Scholar
• Dobson R, Rog D, Ovadia C, et al. Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. Pract Neurol. 2023;23:6-14.
   PubMedGoogle Scholar
• Malek A. Role of IgG antibodies in association with placental function and immunologic diseases in human pregnancy. Expert Rev Clin Immunol. 2013 Mar;9(3):235–249.
   PubMed Web of Science ®Google Scholar
• Howard JF, Utsugisawa K, Benatar M, et al. REGAIN: a randomised, double-blind, placebo-controlled, multi-centre study to evaluate the safety and efficacy of eculizumab in patients with anti-acetylcholine receptor positive refractory generalised myasthenia gravis. Lancet Neurol. 2017;16(12):976–986.
   PubMed Web of Science ®Google Scholar
• Vu T, Harvey B, Suresh N, et al. Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: a case report. Case Rep Neurol. 2021;13(1):65–72.
   PubMed Web of Science ®Google Scholar
• Socie G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019 Apr;185(2):297–310.
   PubMed Web of Science ®Google Scholar
• Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021 Jul;20(7):526–536.
   PubMed Web of Science ®Google Scholar
• Schneider-Gold C, Gilhus NE. Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord. 2021;14:175628642110654. Dec.
   Web of Science ®Google Scholar
• Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management [Review]. Front Neurol. 2020;Nov;11:14.
   Web of Science ®Google Scholar
• Wolfe GIKH, Aban IB, Minisman G, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–522.
   PubMed Web of Science ®Google Scholar
• Tomulescu V, Sgarbura O, Stanescu C, et al. Ten-year results of thoracoscopic unilateral extended thymectomy performed in nonthymomatous myasthenia gravis. Ann Surg. 2011 Nov;254(5):761–766.
   PubMed Web of Science ®Google Scholar
• Grover KM, Sripathi N. Myasthenia gravis and pregnancy. Muscle Nerve. 2020 Dec;62(6):664–672.
   PubMed Web of Science ®Google Scholar
• Altintas A, Dargvainiene J, Schneider-Gold C, et al. Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). Ther Adv Neurol Disord. 2020 Aug;13:175628642094980.
   Web of Science ®Google Scholar
• Cawley S, Mullaney L, McKeating A, et al. A review of European guidelines on periconceptional folic acid supplementation. Eur J Clin Nutr. 2016 Feb;70(2):143–154.
   PubMed Web of Science ®Google Scholar
• Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol. 2007 Jan;14(1):38–43.
   PubMed Web of Science ®Google Scholar
• Nicholls-Dempsey L, Czuzoj-Shulman N, Abenhaim HA. Maternal and neonatal outcomes among pregnant women with myasthenia gravis. J Perinat Med. 2020 Oct;48(8):793–798.
   PubMed Web of Science ®Google Scholar
• Banner H, Niles KM, Ryu M, et al. Myasthenia Gravis in pregnancy: systematic review and case series. Obstet Med. 2022 Jun;15(2):108–117.
   PubMed Web of Science ®Google Scholar
• Tanacan A, Fadiloglu E, Ozten G, et al. Myasthenia gravis and pregnancy: retrospective evaluation of 27 pregnancies in a tertiary center and comparison with previous studies. Ir J Med Sci. 2019 Nov;188(4):1261–1267.
   PubMed Web of Science ®Google Scholar
• Mikkelsen AP, Egerup P, Kolte AM, et al., Pregnancy loss and risk of multiple sclerosis and autoimmune neurological disorder: a nationwide cohort study. PLoS One. 2022;17(3): Mar.
   Web of Science ®Google Scholar
• Thai TN, Sarayani A, Wang X, et al. Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2020 Jun;29(6):716–724.
   PubMed Web of Science ®Google Scholar
• Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014 Aug;52:90–100.
   PubMed Web of Science ®Google Scholar
• Boldingh MI, Maniaol AH, Brunborg C, et al. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology. 2016 Nov;87(20):2139–2145.
   PubMed Web of Science ®Google Scholar
• Su MQG, Liu XQ, Wang L, et al. Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis. Orphanet J Rare Dis. 2022 Feb;17(1):1.
   PubMed Web of Science ®Google Scholar
• Santos E, Braga A, Gabriel D, et al. MuSK myasthenia gravis and pregnancy. Neuromuscul Disord. 2018 Feb;28(2):150–153.
   PubMed Web of Science ®Google Scholar
• Molina G, Weiser TG, Lipsitz SR, et al. Relationship between Cesarean delivery rate and maternal and neonatal mortality. JAMA J Am Med Assoc. 2015 Dec;314(21):2263–2270.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Hong Y. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol. 2018 Dec;25(12):1402–1409.
   PubMed Web of Science ®Google Scholar
• Iijima S. Clinical and pathophysiologic relevance of autoantibodies in neonatal myasthenia gravis. Pediatr Neonatol. 2021 Nov;62(6):581–590.
   PubMed Web of Science ®Google Scholar
• Zisimopoulou P, Brenner T, Trakas N, et al. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev. 2013 Jul;12(9):924–930.
   PubMed Web of Science ®Google Scholar
• Gveric-Ahmetasevic S, Colic A, Elvedji-Gasparovic V, et al. Can neonatal myasthenia gravis be predicted? J Perinat Med. 2008 Nov;36(6):503–506.
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Jacobson LW, Byrne S, et al. Fetal acetylcholine receptor inactivation syndrome A myopathy due to maternal antibodies. Neurol-Neuroimmunol Neuroinflammation. 2015 Feb;2(1):1.
   Google Scholar
• Cetin H, Beeson D, Vincent A, et al. The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle. Front Mol Neurosci. 2020 Sep;13:1-14.
   Web of Science ®Google Scholar
• Hoff JM, Loane M, Gilhus NE, et al. Arthrogryposis multiplexa congenita: an epidemiologic study of nearly 9 million births in 24 EUROCAT registers. Eur J Obstetrics Gynecol Reprod Biol. 2011 Dec;159(2):347–350.
   PubMed Web of Science ®Google Scholar
• Madi A, Bransburg-Zabary S, Maayan-Metzger A, et al. Tumor-associated and disease-associated autoantibody repertoires in healthy colostrum and maternal and newborn cord sera. J Iimmunol. 2015 Jun;194(11):5272–5281.
   PubMed Web of Science ®Google Scholar
• Borba VV, Sharif K, Shoenfeld Y. Breastfeeding and autoimmunity: programing health from the beginning. Am J Reprod Immunol. 2018 Jan;79(1):1-11.
   Web of Science ®Google Scholar
• Bragnes Y, Boshuizen R, de Vries A, et al. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology. 2017 Jun;56(6):1047–1048.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Verschuuren J, Hovland SIB, et al. Myasthenia gravis: do not forget the patient perspective. Neuromuscul Disord. 2021 Dec;31(12):1287–1295.
   Web of Science ®Google Scholar
• Gilhus NE, Hovland SIB. User involvement in Myasthenia gravis research. Front Neurol. 2022 Jun;13:1-5.
   Web of Science ®Google Scholar